TSICM07:	Concomitant Medications of Interest; Safety Analysis Set (Study jjcs - core)						
 	Active Study Agent 	Active Study Agent 	Active Study Agent 	 	 	
Interest Category 	Xanomeline High Dose 	Xanomeline Low Dose 	Combined 	Placebo 	Total 	
  Standardized Medication Name 	N=53 	N=73 	N=126 	N=59 	N=185 	
Steroid 	7 (13.2%) 	9 (12.3%) 	16 (12.7%) 	1 (1.7%) 	17 (9.2%) 	
Hydrocortisone 	7 (13.2%) 	9 (12.3%) 	16 (12.7%) 	1 (1.7%) 	17 (9.2%) 	
 	 	 	 	 	 	
Acetylsalicylic Acid 	0 	1 (1.4%) 	1 (0.8%) 	1 (1.7%) 	2 (1.1%) 	
Acetylsalicylic acid 	0 	1 (1.4%) 	1 (0.8%) 	1 (1.7%) 	2 (1.1%) 	

Note: Concomitant medications are defined as any therapy used on or after the same day as the first dose of study treatment [up to last dose of study treatment +xx days], including those that started before and continue on after the first dose of study treatment. 	
Note: Concomitant medications are defined as any therapy used on or after the same day as the first dose of study treatment [up to last dose of study treatment +xx days], including those that started before and continue on after the first dose of study treatment.	
Note: Concomitant medications are defined as any therapy used on or after the same day as the first dose of study treatment [up to last dose of study treatment +xx days], including those that started before and continue on after the first dose of study treatment.	
Note: Concomitant medications are defined as any therapy used on or after the same day as the first dose of study treatment [up to last dose of study treatment +xx days], including those that started before and continue on after the first dose of study treatment.	
Note: Concomitant medications are defined as any therapy used on or after the same day as the first dose of study treatment [up to last dose of study treatment +xx days], including those that started before and continue on after the first dose of study treatment.	
Note: Concomitant medications are defined as any therapy used on or after the same day as the first dose of study treatment [up to last dose of study treatment +xx days], including those that started before and continue on after the first dose of study treatment.